Opinion|Podcasts|February 5, 2025
Episode 2 Video: Identifying Patients with Intermediate Risk in NMIBC
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
3
Three-year data show durable responses with mitomycin intravesical solution
4
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
5